Hector F. DeLuca,Margaret Clagett-Dame,Lori A. Plum
申请号：
US15666244
公开号：
US20180055856A1
申请日:
2017.08.01
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Disclosed are pharmaceutical compositions and methods of combination therapy that include or utilize low doses of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 and a calcimimetic to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
